Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
Rhea-AI Summary
Anaptys (Nasdaq: ANAB) completed the taxable spin-off of First Tracks Biotherapeutics (trading as TRAX) on April 20, 2026, distributing one First Tracks share per Anaptys share held as of the April 6, 2026 record date. Anaptys now exclusively manages royalties for Jemperli (with GSK) and imsidolimab (with Vanda).
The company says it will operate a virtual model with limited FTEs, minimal operating expenses, approximately $140–$145 million in net cash at launch, and a projected >95% EBIT margin, aiming to protect and return royalty value to shareholders.
Positive
- Spin-off completed on April 20, 2026 with TRAX listing
- $140–$145 million in net cash at launch
- Operating model targets >95% EBIT margin
- Focus narrowed to royalties for Jemperli and imsidolimab
Negative
- Divested former biopharma operations via taxable spin-off
- Reliance on out-licensed royalties limits direct product development upside
News Market Reaction – ANAB
In the Apr 20 session, ANAB declined 24.53%, reflecting a significant negative market reaction. Argus tracked a peak move of +17.0% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Private placement funding | Neutral | -11.7% | First Tracks secured $145M private placement ahead of planned spin-off launch. |
| Mar 27 | Spin-off approval | Neutral | -11.7% | Board formally approved First Tracks spin-off and detailed 1:1 share distribution. |
| Mar 27 | Buyback and update | Positive | -11.7% | Announced $100M repurchase, low-expense royalty model, and post-spin cash position. |
| Mar 03 | Earnings and separation | Positive | +14.6% | Strong Q4 revenue and income plus plan to separate into two public companies. |
| Feb 25 | Partner regulatory update | Positive | -0.5% | Vanda BLA acceptance for imsidolimab in GPP, supporting partnered royalty outlook. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
ANAB showed a strong positive move on earnings but negative or mixed reactions around spin-off, financing, and capital-return announcements, indicating that restructuring and funding news has not consistently supported the share price.
Over recent months, ANAB advanced a major separation strategy, culminating in the spin-off of First Tracks Biotherapeutics. On Mar 3, 2026, it reported strong Q4 2025 results and outlined plans to separate its biopharma operations, with that earnings update driving a 14.61% gain. On Mar 27, 2026, a cluster of events—including a $145M private placement for First Tracks, board approval of the spin-off, and a $100M repurchase plan—coincided with a -11.68% move. Today’s completion of the spin-off formalizes this previously telegraphed transition into a royalty-management model.
Key Terms
ebit margin financial
taxable spin-off regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders
- Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately
$140 -$145 million in net cash
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business.
Anaptys will now exclusively manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda with a focus on protecting and returning the value of its royalties to shareholders.
“Anaptys begins this next chapter in a virtual business model. We are now exclusively managing royalties from our out-licensed assets, Jemperli and imsidolimab, with streamlined operations requiring limited FTEs, minimal operating expenses and providing a greater than
The taxable spin-off was completed today following the distribution to Anaptys shareholders of one share of First Tracks Bio common stock for every one share of Anaptys common stock owned as of the close of business on April 6, 2026, the record date for the distribution.
Anaptys will continue to trade on Nasdaq under the ticker symbol “ANAB”. First Tracks Bio common stock will begin regular-way trading today on the Nasdaq Global Select Market under the symbol “TRAX”.
About AnaptysBio
Anaptys exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to whether Anaptys is able to protect its financial collaborations; and its ability to return value to its shareholders. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to protect its financial collaborations and return value to its shareholders, the company’s ability to operate efficiently with a limited staff, and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
This press release also includes a reference to EBIT margin which is a measure not presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”), which Anaptys believes provides important perspective with respect to operational profitability. Non-GAAP financial measures may exclude items that are significant in understanding and assessing Anaptys’ financial results, should not be considered in isolation or as an alternative to GAAP measures, and should be considered only as a supplement to, and not as superior to, GAAP measures. Anaptys cannot predict with certainty the magnitude or scope of certain items that would be included in the most directly comparable GAAP measure to EBIT margin for the relevant future periods, and such items may be significant. Due to these uncertainties, Anaptys cannot provide a quantitative reconciliation of EBIT margin to the most directly comparable GAAP financial measure without unreasonable effort.
Investor Contact:
Anaptys Investor Relations
investors@anaptysbio.com
